What is a Maximum Allowable Cost (MAC) Law?

Attorneys Jonathan E. Levitt, Esq. and Lucas W. Morgan, Esq. discuss why pharmacies should be aware of when it comes to PBMs and Maximum Allowable Cost (MAC) laws, including:

What is a MAC law? [0:01]
Challenging MAC law/MAC appeals [2:12]

Contact Frier Levitt today to speak to an attorney about Maximum Allowable Cost (MAC) laws.

What is a Maximum Allowable Cost (MAC) Law?

New Jersey Governor Mikie Sherrill Takes Aim at Pharmacy Benefit Managers

Arizona’s Withdrawn GLP-1 Compounding Bill Signals Increased Scrutiny

PBMs Are Targeting Alabama Hospitals with Discriminatory Networks: What 340B Covered Entities Need to Know

A.J. Barbarito Featured in MedCity News: “It Took Years for Congress to Enact PBM Transparency, Delinking. What About Vertical Integration?”

Plan Sponsor Alert: Recent ERISA Decisions Increase Employer Liability Risk for Excessive Fees Paid to Vendors, Brokers, and Service Providers, Including PBMs

Arizona Board of Pharmacy Amendments: Enforcement Caps, Board Continuation, and Ownership Changes

The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry

From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal Signal a New Era for Compounded GLP-1 Drugs

What is a Maximum Allowable Cost (MAC) Law?

Related Insights

New Jersey Governor Mikie Sherrill Takes Aim at Pharmacy Benefit Managers

Arizona’s Withdrawn GLP-1 Compounding Bill Signals Increased Scrutiny

PBMs Are Targeting Alabama Hospitals with Discriminatory Networks: What 340B Covered Entities Need to Know

A.J. Barbarito Featured in MedCity News: “It Took Years for Congress to Enact PBM Transparency, Delinking. What About Vertical Integration?”

Plan Sponsor Alert: Recent ERISA Decisions Increase Employer Liability Risk for Excessive Fees Paid to Vendors, Brokers, and Service Providers, Including PBMs

Arizona Board of Pharmacy Amendments: Enforcement Caps, Board Continuation, and Ownership Changes

The Peptide Landscape Is Shifting: What Secretary Kennedy’s Joe Rogan Interview Could Mean for the Compounding Industry

From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal Signal a New Era for Compounded GLP-1 Drugs